Abstract
Introduction This study evaluated the performance of a wrist-worn wearable, Verily Study Watch (VSW), in detecting key sleep measures against polysomnography (PSG).
Methods We collected data from 41 adults without obstructive sleep apnea or insomnia during a single overnight laboratory visit. We evaluated epoch-by-epoch performance for sleep versus wake classification, sleep stage classification and duration, total sleep time (TST), wake after sleep onset (WASO), sleep onset latency (SOL), sleep efficiency (SE), and number of awakenings (NAWK). Performance metrics included sensitivity, specificity, Cohen’s kappa, and Bland-Altman analyses.
Results Sensitivity and specificity (95% CIs) of sleep versus wake classification were 0.97 (0.96, 0.98) and 0.70 (0.66, 0.74), respectively. Cohen’s kappa (95% CI) for 4-class stage detection was 0.64 (0.18, 0.82). Most VSW sleep measures had proportional bias. The mean bias values (95% CI) were 14.0 minutes (5.55, 23.20) for TST, - 13.1 minutes (-21.33, -6.21) for WASO, 2.97% (1.25, 4.84) for SE, -1.34 minutes (-7.29, 4.81) for SOL, 1.91 minutes (-8.28, 11.98) for light sleep duration, 5.24 minutes (-3.35, 14.13) for deep sleep duration, and 6.39 minutes (-0.68, 13.18) for REM sleep duration. Mean and median NAWK count differences (95% CI) were 0.05 (-0.42, 0.53) and 0.0 (0.0, 0.0), respectively.
Discussion Results support applying the VSW to track overnight sleep measures in free-living settings. Registered at clinicaltrials.gov (NCT05276362).
Competing Interest Statement
S Saeb, BWN, PB, NV, HA, NS, S Sullivan, SP, ER, RK, S Shin report employment and equity ownership in Verily Life Sciences. MDZ, FB and NA received research funding through their institution from Verily Life Sciences for study execution.
Funding Statement
The study was sponsored by Verily Life Sciences
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
WCG Institutional Review Board (20215892) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Study funding statement: The study was sponsored by Verily Life Sciences
Data [/code/materials] sharing statement: Data from this study are not available due to the nature of this program. Participants did not consent for their data to be shared publicly.
Authors’ disclosures: S Saeb, BWN, PB, NV, HA, NS, S Sullivan, SP, ER, RK, S Shin report employment and equity ownership in Verily Life Sciences.
MDZ, FB and NA received research funding through their institution from Verily Life Sciences for study execution.
Data Availability
Data from this study are not available due to the nature of this program. Participants did not consent for their data to be shared publicly.
